Loading
NBTXR3 / Locally Advanced Non Small Cell Lung Cancer · Phase 1/2 Trial
ClinicalTrials.gov · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned phase 1/2 single-arm trial of NBTXR3 (a nanoparticle radiosensitizer) combined with radiation therapy in locally-advanced non-small cell lung cancer patients ineligible for chemotherapy or surgery. The registry record contains no reported outcomes; enrollment is ongoing at a single institution.
Phase 1/2, Interventional, Single Group, Open label, Treatment purpose. Locally-Advanced Non-Small Cell Lung Cancer; age from 18 Years. Intervention: Phase I/II: Treatment with NBTXR3 + Radiation Therapy. n = 40. 1 site: United States.
This is a planned phase 1/2 single-arm trial of NBTXR3 (a nanoparticle radiosensitizer) combined with radiation therapy in locally-advanced non-small cell lung cancer patients ineligible for chemotherapy or surgery. The registry record contains no reported outcomes; enrollment is ongoing at a single institution.
Primary outcome is safety; efficacy endpoints are not specified in this record.
This is an early-stage investigation of a novel nanoparticle radiosensitizer in a patient population with limited treatment options. No efficacy or safety data are yet available in this registry record.
Phase 1/2 single-arm registry record with no posted results; describes a planned study in early-stage development for a novel nanoparticle therapy in lung cancer.
As stated by the source record.
Quoted from the source exactly as published.
This is an early-stage investigation of a novel nanoparticle radiosensitizer in a patient population with limited treatment options. No efficacy or safety data are yet available in this registry record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07224152). This is a study registration, not published results. Lead sponsor: M.D. Anderson Cancer Center. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 40 participants (ESTIMATED). Conditions: Locally-Advanced Non-Small Cell Lung Cancer. Interventions: DRUG: NBTXR3. Primary outcome measures: Safety and Adverse Events (AEs) , Through study completion; an average of 1 year. Brief summary: This is a single institution, single arm phase I/II study of NBTXR3 with radiation therapy for stage I-III advanced non-small cell lung cancer patients who are not candidates for chemotherapy or surgical resection.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.